Pharmaceutical Science-Laundering: Seeding Trials, Ghostwriting, and Data Omission
Three documented tactics that drug companies have used to launder marketing through the scientific literature: {{seeding trials}} disguised as research, {{ghostwriting}} of academic papers, and selective {{data omission}} from published clinical trials.
Three tactics that pharmaceutical companies have used to launder commercial messaging through the scientific literature were extensively documented in the Vioxx case and remain structural features of industry-academic publishing. **Seeding trials.** A seeding trial is a clinical study designed primarily to familiarize prescribing physicians with a drug rather than to answer a genuine scientific question. Merck's ADVANTAGE trial for Vioxx was formally a comparative effectiveness study but internal documents revealed it was designed by the marketing department to get doctors used to prescribing Vioxx. The scientific apparatus — protocol, randomization, publication — was used as a sales funnel. **Ghostwriting.** Internal Merck communications revealed that at least 16 peer-reviewed medical papers on Vioxx had their core analysis drafted by Merck employees or contracted writers, with prestigious academic names added to the byline afterward. The named academic authors often had limited involvement in the underlying analysis. This practice gives commercial conclusions the credibility of independent scholarship without independent scholarship having actually occurred. **Data omission.** The VIGOR trial's 2000 publication in the New England Journal of Medicine omitted three Vioxx heart attacks through a post-hoc manipulation of the data cutoff date. The omission was only discovered five years later when the journal's editorial board published an unprecedented Expression of Concern (Curfman, Morrissey, and Drazen, December 2005) revealing the discrepancy between Merck's submitted data and the actual trial record. These three patterns — designing trials for marketing exposure rather than discovery, attaching academic names to industry-drafted analysis, and selectively presenting data within technically defensible publication conventions — are the playbook that the post-Vioxx FDA Amendments Act of 2007 tried to constrain by mandating public clinical trial results disclosure.